GlassScriptPhysician profile
Hongyan Wang
NPI 1518041888
$741.42
in general payments reported to CMS, 2019-2025
15 companies · $281 in 2025
The $281 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $137 · 2022: $75.63 · 2023: $126 · 2024: $122 · 2025: $281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $529.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $528.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genmab U.S., INC. | $129.50 | 2024-2025 | Epkinly |
| Karyopharm Therapeutics INC. | $83.18 | 2021-2024 | Xpovio |
| Seagen INC. | $82.07 | 2021-2023 | Adcetris |
| Janssen Biotech, INC. | $65.56 | 2024-2025 | Tecvayli, Darzalex, Talvey |
| Incyte Corporation | $53.12 | 2025 | Monjuvi |
| Adc Therapeutics America, INC. | $52.34 | 2023-2024 | |
| Celgene Corporation | $43.84 | 2021-2025 | Reblozyl |
| Sobi, INC | $34.21 | 2025 | |
| Pfizer INC. | $32.09 | 2024 | |
| Genzyme Corporation | $31.44 | 2023 | |
| Abbvie INC. | $29.48 | 2023 | |
| Pharmacyclics LLC, An Abbvie Company | $29.32 | 2021 | |
| Glaxosmithkline, LLC. | $28.06 | 2022 | |
| Morphosys, US INC. | $24.74 | 2021 | |
| Lilly USA, LLC | $22.47 | 2025 | Jaypirca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hongyan Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.